Washington—Among patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), the durability of response from CD19-specific chimeric antigen receptor (CAR) T cells appears to be greater before patients progress to morphologic disease, a new study suggests.
Presenting the data at the 2017 annual meeting of the American Association for Cancer Research, Jae Park, MD, an attending physician in the leukemia service at Memorial Sloan Kettering Cancer Center, in New York